| INTRODUCTION
Barrett's oesophagus is an established pre-malignant condition of the oesophagus that increases the risk of oesophageal adenocarcinoma and dysplasia.
Endoscopic surveillance is often recommended to aid early diagnosis and treatment for dysplasia or cancer. 1, 2 Currently, the American Gastroenterology Association (AGA) guidelines 1 surveillance for patients with nondysplastic Barrett's oesophagus has been questioned. 3 Methods to stratify patients based on risk of progression to oesophageal adenocarcinoma or high-grade dysplasia may help to optimise use of endoscopic resources.
An alternative approach could use a risk prediction model. Providing clinicians with a tool that allows them to estimate a patients' risk may better aid them in deciding surveillance intervals and make future resource utilisation even more efficient. Parasa et al 4 used data from five centres in the United States (US) and one Centre in the Netherlands to develop and internally validate a model to predict progression to oesophageal adenocarcinoma or high-grade dysplasia after an initial diagnosis of Barrett's oesophagus. A model including sex, smoking history (ever vs never), Barrett's oesophagus length (cm) and low-grade dysplasia status, had reasonable discriminatory ability, with an area under the receiver operating characteristic curve of 0.76 (95% CI, 0.72-0.80). However, this prediction tool needs to be validated in an independent population before its use can be recommended in clinical practice. 5 To our knowledge, no external validation has been reported to date.
Using data from the Northern Ireland Barrett's register, we aimed to externally validate the model derived by Parasa et al 4 (including sex, smoking history (ever vs never), Barrett's oesophagus length and low-grade dysplasia status). We also examined whether additional factors not examined in the derivation study may help to improve discriminatory performance.
| MATERIALS AND METHODS

| Study population
The Northern Ireland Barrett's register is a population-based register of all adults diagnosed with columnar-lined epithelium of the oesophagus in Northern Ireland since 1993. The methods of the register formation have been previously described. 6 Briefly, the register was created by reviewing pathology reports of all oesophageal biopsies (corresponding to SNOMED2 codes T62* and SNOMED3 codes T56*) logged in Northern Ireland. A standardised set of guidelines was used for creation of the register, and any pathology reports diagnosing histologically confirmed columnar epithelium of the oesophagus, or synonym terms, were deemed to be Barrett's oesophagus. Reports relating to cancer or confined to the oesophagogastric junction were excluded. Patients were considered to have low-grade dysplasia, if the pathologist reported the presence of "low-grade," "mild," "moderate" or "indefinite" dysplasia. 
| Outcomes
Data from subsequent endoscopic biopsies and linkage to the North- 
| Inclusion and exclusion
We limited the sample to individuals with Barrett's oesophagus, | 1275 diagnosis were excluded (n = 58). Individuals without complete data on Barrett's segment length, smoking status and dysplasia status were excluded from the primary analyses (n = 1950, Figure 1 ). Therefore, a total of 1198 individuals were eligible for inclusion and were included in the primary analysis ( Figure 1 ).
| Statistical analysis
The categorical variables were summarised as counts and percentages. The points based model developed by Parasa et al, 4 was used to assign points to each study participant based on male sex (9 points, females: 0 points), ever smoking (5 points (proportion of all progressors reclassified at higher risk -proportion reclassified at lower risk) -(proportion of all nonprogressors reclassified at higher risk -proportion reclassified at lower risk). 9 The NRIs and proportions in each category were calculated when changing from a mimic of the BSG guideline system to the points categories proposed by Parasa et al. 4 For comparison with the previous study, multivariate Cox proportional hazards models were used to assess the association between sex, cigarette smoking, Barrett's segment length and lowgrade dysplasia status and risk of progression to oesophageal adenocarcinoma or high-grade dysplasia (Table 1) .
To assess potential additions to the model proposed by Parasa et al, 4 factors previously associated with risk of progression including age, weight loss, ulceration erosion and gastrooesophageal reflux symptoms 8 were also added to the model individually. If an additional factor was associated with risk of progression (P < 0.05), then the C-statistic of the original model plus each additional factor was assessed.
Sensitivity analyses assessed the area under the curve: when outcomes were limited to oesophageal adenocarcinoma only; when points attributed to individual factors were excluded; when Barrett's segment length was reported as short (<3 cm; 0 points) vs long (≥3 cm; 5 points, chosen to reflect half the potential maximum 10 points assigned to 10 cm segment lengths) rather than by centimeter; and when additionally including individuals with missing/unknown data, with missing/unknown data assigned zero points (total n = 3090).
Analyses were conducted using Stata/IC statistical software (version 14.1, College Station, Texas).
| RESULTS
During 9487 person-years of follow-up (median 7.5 years follow-up starting 12 months after diagnosis), 54 patients with Barrett's oesophagus progressed to oesophageal adenocarcinoma (n = 41) or high-grade dysplasia (n = 13).
Applying the point system to our study cohort, we found that the risk of progression to oesophageal adenocarcinoma or high-grade dysplasia increased by 12% per additional point (HR 1.12, 95% CI 
| Comparison to existing guidelines
The AUROC for predicting risk of progression to oesophageal adenocarcinoma or high-grade dysplasia using the categories proposed by 
| Sensitivity analyses
None of the additional factors tested changed the AUROC when added individually to the model suggested by Parasa et al 4 ( Table 2 ).
In secondary analyses when outcomes were limited to oesophageal adenocarcinoma only, the area under the curve was unchanged, 0.70 (95% CI 0.63-0.78, Table 2 ). Results were largely unchanged when conducting sensitivity analyses assessing model simplification, or inclusion of individuals with unknown/missing data ( Table 2 ).
| DISCUSSION
In an external validation of a previous risk prediction model, 4 was similar but slightly weaker in this study cohort than reported previously, 4 which is to be expected in external validations. One of the limitations discussed by Parasa et al, 4 was that their data relied on patients enrolled at referral academic centres, and data collection began in the mid-1980s when recognition of short-segment Barrett's may have been less widespread, thus may represent higher risk patients. The similarity of our results when using population-based data from the Northern Ireland Barrett's register may be reassuring that the original results are generalisable to broader patient populations. Therefore, this external validation study suggests that the risk prediction model tool could be used for risk-stratification of Barrett's patients following their index endoscopic biopsy to determine surveillance intervals or treatment decisions. This study had several strengths. The Northern Ireland Barrett's register uses population-based data, rather than patients enrolled at referral academic centres that may represent higher risk patients.
Thus, we believe our results are not overestimating the results shown. We also had data on the factors studied prior to subsequent diagnosis of oesophageal adenocarcinoma or high-grade dysplasia, so ensuring appropriate temporality of the associations studied.
Limitations of this study included the smaller sample size than the Parasa et al study, 4 particularly as missing data was common due to the use of case note reviews. It is possible that factors included in this model influenced decisions on the frequency of surveillance, which may cause reverse causality, whereby individuals with these factors may have more opportunities to detect progression. Unfortunately, information on the number of subsequent endoscopies was not available which prevented an assessment of reverse causality.
The historic and real-world nature of the data may mean some lowgrade dysplasia data was not reviewed by an expert histopathologist in line with current guidelines. 2 A longer follow-up period may also
give a more accurate reflection of the true positive predictive value of the tool.
In summary, we are the first population-based study to externally 
